Latest news

Posts about investor

Capital Markets Advisor, Sanjeev Srivastava, interviewed by Maxine Hoover

Beryl Elites: Interview with Capital Markets Advisor, Sanjeev Srivastava

CEO Heltzen interviewed by Maxine Hoover at the Beryl Elites’ Investment Conference in New York City

Beryl Elites: What is Artificial Evolution - an interview with CEO Heltzen

IBT: AI meets enzymes

International Business Times: AI meets enzymes - eXoZymes enables high-yield production of compounds previously impossible to make

CEO Michael Heltzen at the Beryl Elite's 'AI in Life Sciences' panel

Beryl Elites: AI's Billion-dollar Bet on Life Sciences - From Drug Discovery to Patient Impact (panel)

100× scale-up of NCT production achieved

eXoZymes achieves 100× scale-up of NCT production using exozymes, demonstrating near-perfect feedstock conversion

LA Weekly: The Enzyme Frontier: eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma

LA Weekly: The Enzyme Frontier - eXoZymes Unlocks a New Era for Cannabinoid Nutraceuticals and Pharma

Slack Capital report

Slack Capital report: EXOZ is a once-in-a-lifetime opportunity

'The Upside' interview: Michael Heltzen & Lou Basenese

'The Upside' interview: Michael Heltzen & Lou Basenese

Transcript: EXOZ Q3 2025 update

EXOZ 2025 Q3 Update

eXoZymes provides third quarter 2025 update at 5PM EST today